Mindset’s COPE program provides benchmark data to measure success of new psychedelic drug formulations

Mindset and InterVivo Solutions Announce Availability of First Preclinical Psychedelic Benchmark Data from COPE Program

The first psychedelic benchmark data was made available through the Cooperative Psychedelic Evaluation Platform (COPE), a program started by Mindset Pharma Inc. and InterVivo Solutions in March. The benchmark data is used to measure the success of new psychedelic drug formulations and “will undoubtedly help the value assessment of newer psychedelics in development”, according to Chief Scientific Officer of InterVivo. The data on psilocybin suggests that “the clinical exposure levels reported in humans correlates well to exposure and efficacy measures observed in mice”.

PDF of article